The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: a phase I trial

Autor: Siamak Daneshmand, Iris S.G. Brummelhuis, Kamal S. Pohar, Gary D. Steinberg, Manju Aron, Christopher J. Cutie, Kirk A. Keegan, John C. Maffeo, Donald L. Reynolds, Bradley Raybold, Albert Chau, J. Alfred Witjes

Publikováno v: Urologic Oncology-Seminars and Original Investigations, 40, 344.e1-344.e9
Urologic Oncology-Seminars and Original Investigations, 40, 7, pp. 344.e1-344.e9

Contains fulltext : 251844.pdf (Publisher’s version ) (Open Access) OBJECTIVES: Neoadjuvant chemotherapy and radical cystectomy (RC) are underutilized standards of care for the treatment of muscle-invasive bladder cancer (MIBC) due to high patient

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aec0574d13c3a5235535290b6b7ce3be
https://doi.org/10.1016/j.urolonc.2022.02.009